Stereotaxis, Inc. (STXS)
| Market Cap | $95.42M-58.5% |
| Revenue (ttm) | $31.53M |
| Net Income | -$23.60M |
| EPS | -$0.24 |
| Shares Out | 100.86M |
| PE Ratio | n/a |
| Forward PE | -5.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 900,880 |
| Open | $0.89 |
| Previous Close | $0.88 |
| Day's Range | $0.87 - $0.95 |
| 52-Week Range | $0.80 - $2.86 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | $2.67(+181.86%) |
| Earnings Date | Nov 10, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Stereotaxis, Inc. Stock Analysis — InsiderScore
Stereotaxis, Inc. scored higher than 67% of companies evaluated by InsiderBuying, and ranked 20th out of 52 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Stereotaxis, Inc. bought $10.9K of stock across 2 purchases in the last 90 days, the largest of them $10.7K.
The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$STXS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in STXS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STXS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STXS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New STXS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STXS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from STXS’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
